The Claim
Diabetes status is an independent negative predictor of weight loss during GLP-1 receptor agonist therapy, with non-diabetic individuals achieving 2.5 to 4 times greater weight reductions than diabetic individuals using the same agents, as confirmed by meta-regression (β = -1.77, p < 0.001).
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
People without diabetes lose 2.5 to 4 times more weight on GLP-1 receptor agonist drugs than people with diabetes. This difference is independent of other factors and is confirmed by a meta-regression analysis.
See the scientific wording
Diabetes status is an independent negative predictor of weight loss during GLP-1 receptor agonist therapy, with non-diabetic individuals achieving 2.5 to 4 times greater weight reductions than diabetic individuals using the same agents, as confirmed by meta-regression (β = -1.77, p < 0.001).
GLP-1 drugs work by making the brain feel full and slowing stomach emptying. In people with diabetes, the body's cells may be less responsive to GLP-1, so these effects are weaker, leading to less weight loss.
What the research says
1 studyThis study shows that people without diabetes lose much more weight on GLP-1 drugs than people with diabetes, just as the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.